Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

148467 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders.

The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies.

Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antihypertensive and PAP Treatment in Obstructive Sleep Apnea Patients With Hypertension (AHPAP)

NCT05115994

Obstructive Sleep Apnea Hypertension Death, Cardiac +3 more

ACTIVE_NOT_RECRUITING

Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness

NCT00127348

Sleep Apnea Hypertension Cardiovascular Diseases

COMPLETED PHASE4

Cardiovascular Phenotype Study in Patients With Obstructive Sleep Apnea Syndrome

NCT00764218

Obstructive Sleep Apnea Syndrome Hypertension

UNKNOWN EARLY_PHASE1

Long-term Cardiovascular Outcomes in Patients With RH and OSA With or Without Treatment With CPAP

NCT03002558

Hypertension

COMPLETED

CPAP Effect on Vascular Function in Obstructive Sleep Apnea

NCT02623088

Obstructive Sleep Apnea

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Please see attached analysis plan

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension OSA - Obstructive Sleep Apnea MACE Survival Analysis PAP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertension and obstructive sleep apnea (OSA)

Patients with hypertension and positive airway pressure (PAP) treated OSA

Positive airway pressure (PAP)

Intervention Type DEVICE

Intervention as part of routine clinical care. Data from national registries.

OSA alone

Patients with PAP teated OSA but no hypertension

Positive airway pressure (PAP)

Intervention Type DEVICE

Intervention as part of routine clinical care. Data from national registries.

Hypertension control

Patients of control population with hypertension

No interventions assigned to this group

Healthy controls

Control population without hypertension and without OSA

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Positive airway pressure (PAP)

Intervention as part of routine clinical care. Data from national registries.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients starting PAP treatment for OSA in the swedevox registry between 2010-2021 with and without hypertension. Randomly selected controls with and without hypertension from the general population.

Exclusion Criteria

* Patients with manifest cardiovascular disease (stroke, ischemic heart disease, cardiac failure or atrial fibrillation at baseline).
* Patients with kidney failure at baseline.
* Patients with malignant cancer at baseline.
* Subjects with missing data on any of the main variables in the fitted models.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No